Ectopic ACTH-Mediated Cushing Syndrome (CS) from Sporadic Medullary Thyroid Cancer (MTC): An Immunohistochemical (IHC) Confirmation Study

2011 ◽  
pp. P3-66-P3-66
Author(s):  
Venkata G Budharaju ◽  
James R Howe ◽  
Patricia Kirby ◽  
Robert A Robinson ◽  
Kalman Kovacs ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Cushing Syndrome ◽  
Ectopic Acth ◽  
Medullary Thyroid

ACTH-producing medullary thyroid cancer. Clinical case.

2016 ◽  
Vol 62 (4) ◽  
pp. 45-49
Author(s):  
Evgenia I. Marova ◽  
Ludmila Ya. Rozhinskaya ◽  
Iya A. Voronkova ◽  
Oleg V. Remizov ◽  
Anna I. Zavalishina ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Clinical Picture ◽  
Clinical Case ◽  
Medullary Thyroid Cancer ◽  
Diagnostic Errors ◽  
Ectopic Acth Syndrome ◽  
Ectopic Acth ◽  
Medullary Thyroid ◽  
Ectopic Acth Production

Medullary thyroid cancer with ectopic ACTH production - the disease is extremely rare. The literature describes only a few cases of this disease. Rare ectopic ACTH syndrome caused by medullary thyroid cancer, and the diversity of the clinical picture are responsible for numerous diagnostic errors leading to ineffective treatment. In this regard, we consider it expedient to share our own experience in this area.

scholarly journals Vandetanib Successfully Controls Medullary Thyroid Cancer-Related Cushing Syndrome in an Adolescent Patient

2014 ◽  
Vol 99 (9) ◽  
pp. 3055-3059 ◽  
Author(s):  
A. A. Nella ◽  
M. B. Lodish ◽  
E. Fox ◽  
F. M. Balis ◽  
M. M. Quezado ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Cushing Syndrome ◽  
Adolescent Patient ◽  
Medullary Thyroid

Vandetanib in medullary thyroid cancer-related Cushing syndrome: a case report

2019 ◽  
Author(s):  
Tanja Režić ◽  
Ana Matijaca ◽  
Tanja Škorić Polovina ◽  
Srećko Marušić ◽  
Vlatka Pandžić Jakšić
Keyword(s):  
Thyroid Cancer ◽  
Case Report ◽  
Medullary Thyroid Cancer ◽  
Cushing Syndrome ◽  
Medullary Thyroid

scholarly journals ACTH-secreting medullary thyroid cancer: a case series

2017 ◽  
Vol 2017 ◽  
Author(s):  
Ayanthi A Wijewardene ◽  
Sarah J Glastras ◽  
Diana L Learoyd ◽  
Bruce G Robinson ◽  
Venessa H M Tsang
Keyword(s):  
Thyroid Cancer ◽  
Cushing’S Syndrome ◽  
Medullary Thyroid Cancer ◽  
Kinase Inhibitors ◽  
Neuroendocrine Tumour ◽  
Therapeutic Option ◽  
Rare Complication ◽  
Cushing's Syndrome ◽  
Ectopic Acth ◽  
Medullary Thyroid

Summary Medullary thyroid cancer (MTC) is a rare neuroendocrine tumour that originates from the parafollicular cells of the thyroid gland. The most common presentation of MTC is with a single nodule; however, by the time of diagnosis, most have spread to the surrounding cervical lymph nodes. Cushing’s syndrome is a rare complication of MTC and is due to ectopic adrenocorticotrophic hormone (ACTH) secretion by tumour cells. Cushing’s syndrome presents a challenging diagnostic and management issue in patients with MTC. Tyrosine kinase inhibitors (TKI) previously used for the management of metastatic MTC have become an important therapeutic option for the management of ectopic ACTH in metastatic MTC. The article describes three cases of ectopic ACTH secretion in MTC and addresses the significant diagnostic and management challenges related to Cushing’s syndrome in metastatic MTC. Learning points: Medullary thyroid cancer (MTC) is a rare neuroendocrine tumour. Cushing’s syndrome is a rare complication of MTC that has a significant impact on patients’ morbidity and mortality. Tyrosine kinase inhibitors (TKI) provide an important therapeutic option for the management of ectopic ACTH in metastatic MTC.

Abstract #1101 The Value of Calcitonin Calcium Stimulation Test Levels as Predictors of Medullary Thyroid Cancer.

2018 ◽  
Vol 24 ◽  
pp. 273-274
Author(s):  
Corin Badiu ◽  
Mara Baet ◽  
Ruxandra Dobrescu ◽  
Andra Caragheorgheopol ◽  
Corneci Cristina
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Stimulation Test ◽  
Medullary Thyroid ◽  
Calcium Stimulation

Immunoscintigraphy in Medullary Thyroid Cancer Using an 123I- or 111ln-Labelled Monoclonal Anti-CEA Antibody Fragment

1986 ◽  
Vol 25 (06) ◽  
pp. 227-231 ◽  
Author(s):  
Chr. Eilles ◽  
W. Spiegel ◽  
W. Becker ◽  
W. Börner ◽  
Chr. Reiners
Keyword(s):  
Bone Marrow ◽  
Thyroid Cancer ◽  
Potassium Iodide ◽  
Medullary Thyroid Cancer ◽  
Elevated Serum ◽  
Antibody Fragment ◽  
Special Importance ◽  
Medullary Thyroid ◽  
Medullary Cancer ◽  
Serum Cea

The monoclonal anti-CEA F(ab’)2 fragment MAb BW 431/31, labelled with 123I or111 In, was used for immunoscintigraphy (IS) in 9 patients with medullary cancer of the thyroid (CCC). The results of 11 studies lead to the following conclusions: 1) When using radioiodine as a label for MAb in IS, potassium iodide is absolutely necessary to block the thyroid which is of special importance in patients with thyroid cancer; 2) Preinjection of “cold” MAb reduces the relatively high unspecific uptake (especially in bone marrow) of MAb BW 431/31, which is of special importance for the antibody labelled with 111 In; 3) IS with MAb BW 413/31 in patients with CCC and elevated serum CEA is positive only in cases with large secondaries; and 4) In patients with CCC and several manifestations of secondaries, only a single (large) metastasis may be apparent.

Sign in / Sign up

Export Citation Format

Share Document